SCHEMBL2942929

SCHEMBL2942929

COC(=O)COc1ccc(Cl)cc1Cc1ccccc1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 3/20 0.49
PTGDR Q13258 2/20 0.49
MAPT P10636 5/20 0.46
LMNA P02545 3/20 0.46
ANO1 Q5XXA6 2/20 0.46
ANO2 Q9NQ90 1/20 0.46
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
F2 P00734 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 2/20 0.43
GAA P10253 1/20 0.43
SLC22A1 O15245 1/20 0.43
USP2 O75604 1/20 0.43
HSP90AA1 P07900 1/20 0.43
CYP3A4 P08684 1/20 0.43
HSPD1 P10809 1/20 0.43
HSPA5 P11021 1/20 0.43
IDO1 P14902 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4627039 0.91 PTGDR2 (0.52) PTGDR2PTGDRMAPTLMNAANO1
SCHEMBL4627361 0.89 PTGDR (0.58) PTGDR2PTGDRMAPTLMNATSHR
SCHEMBL2944261 0.86 MAPT (0.63) PTGDR2PTGDRMAPTTSHRTDP1
SCHEMBL11069880 0.85 PTGER1 (0.54) PTGDR2PTGDRMAPTLMNATSHR
SCHEMBL4626978 0.84 MAPT (0.65) PTGDR2PTGDRMAPTLMNATSHR
SCHEMBL4656398 0.82 PTGER1 (0.52) PTGDR2PTGDRF2PTGER1
SCHEMBL4627047 0.82 PTGDR2 (0.47) PTGDR2PTGDRMAPTLMNATSHR
SCHEMBL2945768 0.81 TSHR (0.48) PTGDR2PTGDRMAPTANO1ANO2
SCHEMBL2945278 0.80 MAPT (0.70) PTGDR2PTGDRMAPTLMNATSHR
SCHEMBL2944675 0.79 PTGDR (0.55) PTGDR2PTGDRMAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678826-B2 Organic compounds for the treatment of inflammatory or allergic conditions NOVARTIS AG (CH) 2010-03-16 US disclosed
EP-1891029-B1 ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS NOVARTIS AG (CH) 2010-01-06 EP disclosed
US-20080200466-A1 Organic Compounds For the Treatment of Inflammatory or Allergic Conditions NOVARTIS AG (CH) 2008-08-21 US disclosed
EP-1891029-A1 ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS Novartis AG (CH) 2008-02-27 EP disclosed
WO-2006125596-A1 ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS NOVARTIS AG (CH) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200466-A1 Organic Compounds For the Treatment of Inflammatory or Allergic Conditions HRH2, MRGPRX2, HRH1 PTGDR2 43/4885PTGDR 36/4885MAPT 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.